EV-Based Liquid Biopsy Market, By Biomarker Type (Proteins, RNA (miRNA, mRNA, etc.), DNA, and Lipids), By Sample Type, By Application, By End-user, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4198
|
Published Date
July 2025
|
Pages
365
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
EV-Based Liquid Biopsy Market size was valued at US$ 355.23 Million in 2024, expanding at a CAGR of 19.5% from 2025 to 2032.
The EV-based liquid biopsy market is centered on the use of extracellular vesicles (EVs) as a non-invasive diagnostic tool. EVs are nano-sized particles naturally released by cells into bodily fluids such as blood, saliva, and urine. These vesicles carry essential biological materials—such as RNA, DNA, proteins, and lipids—that reflect the physiological or pathological state of their cells of origin. This makes EVs highly valuable for disease detection and monitoring, particularly in oncology. Unlike traditional tissue biopsies, EV-based liquid biopsies offer a less invasive alternative, minimizing patient discomfort while enabling real-time monitoring of disease progression. They are especially useful for detecting tumors that are difficult to access or track using conventional diagnostic methods.
The growing emphasis on precision medicine, early disease detection, and minimally invasive diagnostics is driving increased adoption of EV-based technologies. One of their key advantages is their greater stability in circulation compared to other biomarkers, which enhances their reliability in clinical settings. The market is experiencing strong growth fueled by advances in EV isolation techniques, expanding clinical research, and the widening range of applications in cancer, neurological disorders, and infectious diseases. However, challenges such as the lack of standardization, limited regulatory frameworks, and technical variability still need to be addressed. Despite these hurdles, EV-based liquid biopsy is rapidly emerging as a powerful and promising approach in the future of diagnostics.
EV-Based Liquid Biopsy Market- Market Dynamics
The increasing implementation of hospital-acquired infection (HAI) control protocols is driving the demand for needle destroyers.
A key niche driver of the EV-based liquid biopsy market is the increasing demand for non-invasive cancer monitoring using extracellular vesicle (EV) biomarkers. Traditional cancer diagnostics often rely on tissue biopsies, which can be invasive, painful, and sometimes impractical—especially for tumors located in hard-to-reach areas. In contrast, EVs released by cancer cells into body fluids carry genetic and proteomic information that closely reflects the tumor’s molecular profile, offering a less invasive yet highly informative diagnostic alternative.
The ability to use simple fluid samples, such as blood, for serial sampling allows clinicians to monitor cancer progression, treatment response, or recurrence in real time—without subjecting patients to repeated invasive procedures. Moreover, EVs are more stable in circulation than other biomarkers, such as cell-free DNA, which enhances the accuracy and reliability of test results. As oncology increasingly adopts personalized and precision medicine, EV-based liquid biopsies are emerging as valuable tools for guiding tailored treatment strategies. They are especially critical in cases where traditional tissue biopsy is not feasible due to patient health constraints or tumor inaccessibility.
Global government initiatives are also supporting the growth of this market. Agencies like the U.S. National Cancer Institute (NCI), the European Commission, and the World Health Organization (WHO) are investing in research and regulatory frameworks to promote the development and adoption of non-invasive diagnostic technologies. Funding programs and public health policies aimed at improving early cancer detection and personalized treatment are accelerating the clinical integration of EV-based liquid biopsies worldwide. This rising clinical demand, backed by governmental support, is driving ongoing innovation, research, and investment in EV-based diagnostics, solidifying their role in the future of cancer care.
EV-Based Liquid Biopsy Market- Segmentation Analysis:
The Global EV-Based Liquid Biopsy Market is segmented based on Biomarker Type, Sample Type, Application, End-user, and Region.
The extracellular vesicle (EV)-based liquid biopsy market is segmented into five biomarker types: Proteins, RNA (including microRNA [miRNA] and messenger RNA [mRNA]), DNA, Lipids, and Others. Among these, RNA biomarkers, particularly miRNA and mRNA, represent the most dominant segment. This is largely due to RNA’s vital role in reflecting the genetic activity of the cells from which EVs originate, especially cancer cells. EVs carry stable RNA molecules that provide critical insights into gene expression patterns, facilitating early disease detection and ongoing monitoring. Compared to other biomolecules, RNA biomarkers offer superior specificity and sensitivity, which are essential for precise diagnosis and prognosis. miRNAs, in particular, regulate key cellular processes and have been strongly linked to tumor progression, making them powerful indicators in liquid biopsy applications. Furthermore, advancements in RNA sequencing and analytic technologies have greatly enhanced the reliability of detecting and quantifying EV-associated RNAs. The increasing emphasis on personalized medicine further fuels the adoption of RNA biomarkers, as they enable treatments tailored to an individual’s molecular profile. Although isolating pure RNA from EVs remains technically challenging, ongoing research is steadily overcoming these obstacles, solidifying RNA’s pivotal role as a growth driver in the EV-based liquid biopsy market. According to the World Health Organization (WHO), cancer accounts for nearly 10 million deaths annually worldwide, highlighting the urgent need for improved diagnostic tools such as RNA-based liquid biopsies.
The market is also categorized by application into Cancer Diagnostics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, and Others. Among these, Cancer Diagnostics stands out as the most dominant application segment in the EV-based liquid biopsy market. This dominance is driven by the critical need for early, accurate, and minimally invasive diagnostic methods to detect and monitor cancer. EVs released by tumor cells carry molecular signatures—including proteins, RNA, and DNA—that offer real-time information about tumor presence, progression, and response to treatment. Unlike conventional tissue biopsies, EV-based liquid biopsies enable continuous monitoring through simple blood or body fluid samples, thereby reducing patient discomfort and facilitating earlier clinical intervention. The rising global cancer burden, combined with a growing focus on personalized medicine, has accelerated the adoption of EV-based diagnostics in oncology. Moreover, these liquid biopsies prove particularly valuable for detecting tumors that are challenging to access or monitor via traditional methods. Numerous research initiatives and clinical trials continue to validate the clinical efficacy of EV biomarkers in cancer detection, establishing cancer diagnostics as the primary driver of growth in this market. While applications in infectious diseases and neurological disorders are emerging, cancer diagnostics currently remain the central focus of EV-based liquid biopsy development and commercialization worldwide.
EV-Based Liquid Biopsy Market- Geographical Insights
In North America, the EV-based liquid biopsy market is gaining significant momentum, driven by advanced healthcare infrastructure and the early adoption of innovative diagnostic technologies. The region benefits from a strong research ecosystem supported by leading academic institutions, biotechnology companies, and government funding initiatives focused on cancer diagnostics. Increasing awareness among healthcare professionals about the clinical potential of extracellular vesicles for non-invasive disease detection and monitoring is further propelling market growth. The integration of EV-based tests into clinical practice is supported by well-established regulatory frameworks and a growing number of ongoing clinical trials.
The United States leads the North American market, fueled by its sophisticated healthcare system and strong emphasis on early cancer detection. The country’s robust research landscape, comprising top academic institutions and biotech firms, drives continuous innovation in diagnostic technologies. Rising preference among clinicians and patients for non-invasive diagnostic methods has accelerated the adoption of EV-based liquid biopsies, which provide real-time insights into disease progression and treatment response. The U.S. Food and Drug Administration (FDA) plays a critical role in overseeing these emerging technologies, ensuring they meet rigorous safety and efficacy standards.
Globally, government agencies such as the World Health Organization (WHO), the European Commission, and the U.S. National Cancer Institute (NCI) are investing heavily in research and regulatory support for non-invasive diagnostic tools like EV-based liquid biopsies. These initiatives aim to standardize testing protocols and promote the adoption of advanced diagnostics for early disease detection and personalized treatment across regions. Nonetheless, challenges remain, including the need to establish standardized protocols for EV isolation and analysis to ensure consistent and reliable results worldwide.
EV-Based Liquid Biopsy Market- Competitive Landscape:
The competitive landscape of the EV-based liquid biopsy market is shaped by a mix of established biotech firms and innovative startups specializing in extracellular vesicle technologies. Leading companies such as Exosome Diagnostics, Thermo Fisher Scientific, and Qiagen leverage their strong research capabilities and global presence to drive advancements in EV-based diagnostics. Bio-Techne Corporation and NanoView Biosciences are also making significant contributions through cutting-edge innovations in EV detection and characterization. Meanwhile, firms like System Biosciences (SBI), Miltenyi Biotec, and AMSBIO offer specialized EV isolation and analysis kits, catering to diverse research needs. Emerging companies including Exosomics S.p.A., Codiak BioSciences, and VivaZome Therapeutics are intensifying competition by developing novel EV-based platforms focused on oncology and personalized medicine applications. The market remains highly dynamic, with strategic collaborations, research partnerships, and clinical validations playing crucial roles in defining competitive positioning. As regulatory pathways become more established, these companies are poised to expand their footprint within clinical settings.
Recent Developments:
- In October 2024, Qiagen expanded its automated liquid biopsy portfolio to enhance applications in oncology, prenatal care, and organ transplantation. The upgraded ccfDNA Kit, now including a urine protocol compatible with EZ1 and EZ2 instruments, aims to streamline liquid biopsy workflows for cancer research. Additionally, the QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality circulating free DNA (cfDNA) suitable for various downstream applications, reinforcing Qiagen’s commitment to advancing liquid biopsy technologies.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL EV-BASED LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Exosome Diagnostics
- Bio-Techne Corporation
- Thermo Fisher Scientific
- NanoView Biosciences
- System Biosciences (SBI)
- Qiagen
- Norgen Biotek Corp.
- BioVision Inc.
- Miltenyi Biotec
- Creative Biolabs
- AMSBIO
- Exosomics S.p.A
- NX Pharmagen
- VivaZome Therapeutics
- Aethlon Medical
- Evox Therapeutics
- Capricor Therapeutics
- Codiak BioSciences
- Anjarium Biosciences
- HansaBioMed Life Sciences
GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032
- Proteins
- RNA (miRNA, mRNA, etc.)
- DNA
- Lipids
- Others
GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
- Others
GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Cancer Diagnostics
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Diseases
- Others
GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals & Clinics
- Research Institutes
- Diagnostic Laboratories
- Biopharmaceutical Companies
- Others
GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. EV-Based Liquid Biopsy Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. EV-Based Liquid Biopsy Market Snippet by Biomarker Type
2.1.2. EV-Based Liquid Biopsy Market Snippet by Sample Type
2.1.3. EV-Based Liquid Biopsy Market Snippet by Application
2.1.4. EV-Based Liquid Biopsy Market Snippet by End-user
2.1.5. EV-Based Liquid Biopsy Market Snippet by Country
2.1.6. EV-Based Liquid Biopsy Market Snippet by Region
2.2. Competitive Insights
3. EV-Based Liquid Biopsy Key Market Trends
3.1. EV-Based Liquid Biopsy Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. EV-Based Liquid Biopsy Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. EV-Based Liquid Biopsy Market Opportunities
3.4. EV-Based Liquid Biopsy Market Future Trends
4. EV-Based Liquid Biopsy Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. EV-Based Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. EV-Based Liquid Biopsy Market Landscape
6.1. EV-Based Liquid Biopsy Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. EV-Based Liquid Biopsy Market – By Biomarker Type
7.1. Overview
7.1.1. Segment Share Analysis, By Biomarker Type, 2024 & 2032 (%)
7.1.2. Proteins
7.1.3. RNA (miRNA, mRNA, etc.)
7.1.4. DNA
7.1.5. Lipids
7.1.6. Others
8. EV-Based Liquid Biopsy Market – By Sample Type
8.1. Overview
8.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
8.1.2. Blood
8.1.3. Urine
8.1.4. Saliva
8.1.5. Cerebrospinal Fluid
8.1.6. Others
9. EV-Based Liquid Biopsy Market – By Application
9.1. Overview
9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
9.1.2. Cancer Diagnostics
9.1.3. Infectious Diseases
9.1.4. Neurological Disorders
9.1.5. Cardiovascular Diseases
9.1.6. Others
10. EV-Based Liquid Biopsy Market – By End-user
10.1. Overview
10.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
10.1.2. Hospitals & Clinics
10.1.3. Research Institutes
10.1.4. Diagnostic Laboratories
10.1.5. Biopharmaceutical Companies
10.1.6. Others
11. EV-Based Liquid Biopsy Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. EV-Based Liquid Biopsy Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. EV-Based Liquid Biopsy Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. EV-Based Liquid Biopsy Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. EV-Based Liquid Biopsy Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. EV-Based Liquid Biopsy Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- EV-Based Liquid Biopsy Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Exosome Diagnostics
12.2.2. Bio-Techne Corporation
12.2.3. Thermo Fisher Scientific
12.2.4. NanoView Biosciences
12.2.5. System Biosciences (SBI)
12.2.6. Qiagen
12.2.7. Norgen Biotek Corp.
12.2.8. BioVision Inc.
12.2.9. Miltenyi Biotec
12.2.10. Creative Biolabs
12.2.11. AMSBIO
12.2.12. Exosomics S.p.A
12.2.13. NX Pharmagen
12.2.14. VivaZome Therapeutics
12.2.15. Aethlon Medical
12.2.16. Evox Therapeutics
12.2.17. Capricor Therapeutics
12.2.18. Codiak BioSciences
12.2.19. Anjarium Biosciences
12.2.20. HansaBioMed Life Sciences
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
